Vol. 43 (2): 184-187, March – April, 2017
doi: 10.1590/S1677-5538.IBJU.2017.02.03
DIFFERENCE OF OPINION
Leonardo L. Monteiro 1, Wassim Kassouf 1
1 Division of Urology, McGill University Health Center, Montreal, Quebec, Canada
Keywords: Urinary Bladder Neoplasms; Cystectomy; Chemoradiotherapy, Adjuvant; Neoadjuvant Therapy
Around the World, radical cystectomy (RC) with bilateral pelvic lymphadenectomy (PLND) and perioperative chemotherapy is regarded as the standard treatment for patients with muscle-invasive bladder cancer (MIBC). This management approach is supported by numerous renowned organizations and guidelines, such as the National Comprehensive Cancer Network (NCCN), as well as by the European Association of Urology (EAU) guidelines.
In fact, the latter has assigned RC a grade A recommendation for treating MIBC (T2-T4aN0M0) and high-risk non-muscle invasive bladder cancer.
